Early posttransplant characteristics and complications at 30 days of patients who underwent allogeneic hematopoietic cell transplantation in the overall cumulative incidence estimation cohort (n = 1857)
| . | Values . |
|---|---|
| VTE-related events (%) | |
| New diagnosis of VTE | 33 (1.8) |
| CR-DVT | 21 (1.1) |
| PE or LE-DVT | 12 (0.6) |
| Anticoagulation usage (%) | 105 (5.7) |
| New initiation of prophylactic or therapeutic anticoagulation (excluded from model derivation) | |
| Hospitalization and death | |
| Days of hospitalization, median (IQR) | 15 (2-22) |
| Inpatient admission at 30 d, n (%) | 298 (16.1) |
| Mortality at 30 d, n (%) (excluded from model derivation) | 49 (2.6) |
| Neutrophil engraftment | |
| Days to neutrophil engraftment >0.5 × 109/L, median (IQR) | 17 (14-20) |
| Neutrophil engraftment at 30 d, n (%) | 1812 (97.6) |
| Platelet engraftment >50 | |
| Days to platelet engraftment >50 × 109/L, median (IQR) | 14 (12-24) |
| Platelet recovery >50 at 30 d, n (%)* | 1406 (75.7) |
| Platelet engraftment >20 | |
| Days to platelet engraftment >20 × 109/L, median (IQR) | 13 (10-19) |
| Platelet recovery >20 at 30 d, n (%)* | 1543 (83.1) |
| Acute GVHD (%) | |
| None or grade 1 | 1203 (64.8) |
| Grade 2 | 515 (27.7) |
| Grade 3 to 4 | 139 (7.5) |
| Systemic infections (%) | |
| Bacteremia | 358 (19.3) |
| Invasive aspergillosis infection | 156 (8.4) |
| CMV reactivation | 395 (21.8) |
| Laboratory values at day 30, median (IQR) | |
| White blood cell count, ×109/L | 5.1 (3.2-7.9) |
| Absolute neutrophil count, ×109/L | 3.3 (1.9-5.6) |
| Hemoglobin, g/dL | 10.7 (9.8-11.6) |
| Platelets, ×109/L | 102 (56-153) |
| Creatinine, mg/dL | 1.0 (0.8-1.3) |
| Total bilirubin, mg/dL | 0.7 (0.5-1.1) |
| International normalized ratio | 1.1 (1.1-1.3) (n = 718) |
| Partial thromboplastin time, s | 33 (28-40) (n = 624) |
| D-dimer, μg/mL | 2.8 (1.6-4.6) (n = 124) |
| . | Values . |
|---|---|
| VTE-related events (%) | |
| New diagnosis of VTE | 33 (1.8) |
| CR-DVT | 21 (1.1) |
| PE or LE-DVT | 12 (0.6) |
| Anticoagulation usage (%) | 105 (5.7) |
| New initiation of prophylactic or therapeutic anticoagulation (excluded from model derivation) | |
| Hospitalization and death | |
| Days of hospitalization, median (IQR) | 15 (2-22) |
| Inpatient admission at 30 d, n (%) | 298 (16.1) |
| Mortality at 30 d, n (%) (excluded from model derivation) | 49 (2.6) |
| Neutrophil engraftment | |
| Days to neutrophil engraftment >0.5 × 109/L, median (IQR) | 17 (14-20) |
| Neutrophil engraftment at 30 d, n (%) | 1812 (97.6) |
| Platelet engraftment >50 | |
| Days to platelet engraftment >50 × 109/L, median (IQR) | 14 (12-24) |
| Platelet recovery >50 at 30 d, n (%)* | 1406 (75.7) |
| Platelet engraftment >20 | |
| Days to platelet engraftment >20 × 109/L, median (IQR) | 13 (10-19) |
| Platelet recovery >20 at 30 d, n (%)* | 1543 (83.1) |
| Acute GVHD (%) | |
| None or grade 1 | 1203 (64.8) |
| Grade 2 | 515 (27.7) |
| Grade 3 to 4 | 139 (7.5) |
| Systemic infections (%) | |
| Bacteremia | 358 (19.3) |
| Invasive aspergillosis infection | 156 (8.4) |
| CMV reactivation | 395 (21.8) |
| Laboratory values at day 30, median (IQR) | |
| White blood cell count, ×109/L | 5.1 (3.2-7.9) |
| Absolute neutrophil count, ×109/L | 3.3 (1.9-5.6) |
| Hemoglobin, g/dL | 10.7 (9.8-11.6) |
| Platelets, ×109/L | 102 (56-153) |
| Creatinine, mg/dL | 1.0 (0.8-1.3) |
| Total bilirubin, mg/dL | 0.7 (0.5-1.1) |
| International normalized ratio | 1.1 (1.1-1.3) (n = 718) |
| Partial thromboplastin time, s | 33 (28-40) (n = 624) |
| D-dimer, μg/mL | 2.8 (1.6-4.6) (n = 124) |
Platelet recovery was defined as platelet count >50 or 20 × 109/L without platelet transfusion for at least 7 d.